Dr Goran Ando joins Xeophin as Chairman of the Clinical Advisory Committee
Xeophin Pty Ltd has announced the appointment of Dr Goran Ando to the team as Chairman of the Clinical Advisory Committee.
The team here at Xeophin are very pleased to announce the appointment of Dr Ando to Xeophin’s Clinical Advisory Committee. Dr Ando's helps solidify Xeophin and it’s technology’s position within the Biotechnology space as a compelling anti-inflammatory business. Dr Ando’s extensive experience in the Pharmaceutical Industry will not only benefit Xeophin in executing a successful clinical strategy, but will also serve to give confidence to the wider capital markets that Xeophin’s value and clinical outcomes are driven by Dr Ando’s legacy of leadership in both the Pharmaceutical Industries and the Venture Capital space.
Dr Ando has held the position of Chairman of Novo Nordisk A/S since 2013, and has been on the board since 2005, being re-elected several times throughout his tenure. Dr Ando is a specialist in general medicine and a founding fellow of the American College of Rheumatology in the US. Dr Ando serves as chairman of the board of Symphogen A/S, Denmark and as a board member of Novo Holdings A/S, Denmark, Molecular Partners AG, Switzerland, EUSA Pharma Ltd., UK, and ICMEC, US. Dr Ando also serves as a Senior Advisor to Essex Woodlands Healthcare Partners, UK.
Mr Troy Neilson, Xeophin’s Chief Executive Officer stated, “Dr Ando is internationally renowned for his leadership of Novo Nordisk A/S. His guidance, vision and passion are going to be invaluable in building Xeophin’s partnership networks, and providing strategic leadership to our clinical team”. Mr Neilson also stated, “On a personal note, and I think that I can speak for the rest of the team when I say that we’re very much looking forward to working with Dr Ando, and drawing on his extensive understanding of the space.”